Shannon Dahl

Shannon Dahl Email and Phone Number

Visionary Biotechnology Executive, Chief Scientific Officer, Board Advisor || Driving Innovation from Discovery to Go-to-Market || Offering Expertise in R&D, Commercialization, and Strategic Growth @ Carve Bio
Shannon Dahl's Location
San Francisco Bay Area, United States, United States
Shannon Dahl's Contact Details
About Shannon Dahl

Driving Therapeutic Innovation from Discovery to CommercializationI am a visionary leader in the biotechnology industry with a longstanding reputation for transforming groundbreaking scientific research into market-ready therapies that save lives. With a strong foundation in scientific strategy and business development, I excel at guiding high-growth biotech companies through the critical phases of development. My unique blend of expertise allows me to navigate the complexities of R&D, regulators, commercialization, and reimbursement – guaranteeing that innovative therapies reach the patients who need them most.Over the course of my executive career, I have gained a holistic understanding of the biotech landscape, from early-stage research to Phase 3 clinical trials and reimbursement, as well as the growth of companies through these stages. My strategic insights have often been the key to securing significant funding, forging strategic partnerships, and building high-performing teams. Whether I’m developing a unified vision for teams to develop new therapies or I’m negotiating value-based care agreements or engaging with a range of critical stakeholders, I bring a forward-thinking approach to every project to drive success at every stage.One of my passions is supporting development of new therapeutics. I balance both a business mindset and a scientific outlook, and I am proud of the skills and areas of expertise I’ve built in my career, including:• R&D Strategy & Operations• Therapeutic Pipeline Strategy & Operations• Clinical Translation, Clinical Endpoints, and KOL Engagement• Payer Relationships and Pathways to Reimbursement • Commercialization • Strategic Partnerships and Fundraising• Executive Leadership and Team Building• Translational Research • Biomanufacturing and GMP ProcessesAs a trusted strategic advisor and board member, I have guided numerous biotech startups to achieve their goals by enabling substantial growth, sparking innovation, and capturing and communicating the value created. I am motivated by a commitment to excellence and a passion for advancing healthcare, and I continuously look for new opportunities to make a meaningful impact. Let's connect and talk about the next wave of biotech innovation. Feel free to reach out to me here on LinkedIn!

Shannon Dahl's Current Company Details
Carve Bio

Carve Bio

View
Visionary Biotechnology Executive, Chief Scientific Officer, Board Advisor || Driving Innovation from Discovery to Go-to-Market || Offering Expertise in R&D, Commercialization, and Strategic Growth
Shannon Dahl Work Experience Details
  • Carve Bio
    Founder And Chief Executive Officer (Ceo)
    Carve Bio Oct 2021 - Present
    I lead a boutique consulting firm that provides fractional CSO or CSO/CBO roles, strategic consulting, and reimbursement strategy, with a focus on immunology or cell & gene therapy. We serve VC-backed, PE-backed, and public biotech therapeutics companies to guide them through critical development phases and achieve their scientific and commercial objectives.Working fractionally, I maximize value creation by developing innovative product strategies and driving drug development. I navigate complex regulatory and reimbursement landscapes, secure substantial funding, and build strong partnerships that position my clients for long-term success. Through Carve Bio, I have supported numerous high-growth biotech clients – driving their projects from early-stage research and funding through the path to commercialization and reimbursement.
  • Iolyx Therapeutics
    Chief Scientific Officer
    Iolyx Therapeutics Jan 2022 - Present
    I direct scientific, translational, and strategic initiatives for therapies at the intersection of autoimmunity and ophthalmology, enabling clinical translation of the lead and building a pipeline.
  • Digitalis Commons
    Expert-In-Residence (Xir)
    Digitalis Commons Aug 2024 - Present
    I advise ARPA-H on how to shape their funding programs, to enable successful translation from transformative R&D to commercialization.
  • Radar Therapeutics
    Strategic Advisor
    Radar Therapeutics Oct 2023 - Present
    Radar is developing genetic medicines to read the cell’s profile, and to only make medicines in the right cells, at the right time. I advise on development and strategy.
  • Laguna Bio
    Strategic Advisor
    Laguna Bio Aug 2024 - Present
    Berkeley, Ca, Us
  • Laguna Bio
    Chief Scientific Officer
    Laguna Bio Nov 2023 - Aug 2024
    Berkeley, Ca, Us
    Contributed to the development of a novel immunotherapy for cancer, designed to activate and expand the immune system by leveraging the evolutionary interplay between microbes and immune cells. I defined translational research and regulatory strategies to facilitate clinical translation into new indications, and shaped the supporting scientific story.
  • Strand Therapeutics
    Strategic Advisory Board
    Strand Therapeutics 2019 - Present
    Boston, Massachusetts, Us
    Strand Therapeutics is utilizing synthetic biology to genetically program mRNA, and is initially focused on therapies for cancer treatment. I provided strategic guidance on team growth, and on translational CMC strategies for regulators, enabling therapeutic advancement and company growth. Company raised $97M Series A and initiated first-in-human trial.
  • Hepatx Corporation
    Scientific Advisory Board
    Hepatx Corporation 2017 - 2024
    Palo Alto, Ca, Us
    This company is dedicated to developing liver regeneration therapies. I advised on R&D, critical attributes of liver cell therapy, and datasets for regulators, which led to a positive FDA Interact Meeting.
  • Epic Bio
    Chief Business Advisor
    Epic Bio Feb 2023 - Sep 2023
    I advised on strategic partnerships and business operations for an innovative epigenetic gene regulation platform, positioning the company for a successful strategic collaboration and further growth after their $55M Series A.
  • 4:59 Newco, A 5Am Ventures Company
    Interim Chief Scientific Officer
    4:59 Newco, A 5Am Ventures Company Oct 2021 - Apr 2022
    Boston, Ma, Us
    Functioned as the interim CSO of Diagon Therapeutics, a stealth allogeneic iPSC-derived cell therapy platform company seed funded by 5AM, Qiming, MRL, JDRF T1D Fund, and CCRM. I built high-functioning teams across immunology, computational biology, functional genomics, cell biology, and nonclinical, and defined high priority focus areas and product success criteria.
  • Cell Care Therapeutics
    Chief Scientific Officer
    Cell Care Therapeutics 2018 - Aug 2021
    Monrovia, California, Us
    My role included defining a unified scientific, clinical, regulatory, and commercial vision for miRNA exosome therapies that were immune-modulating for inflammation-driven diseases in ophthalmology and pulmonology, and then optimizing scientific and strategic initiatives to advance preclinical programs and scalable manufacturing. I also transformed company culture, built and led high-performing teams, established new strategic relationships, and delivered significant growth through innovation. Under my leadership, the team transformed the company’s vision into reality and advanced our therapeutic pipeline.
  • Humacyte
    Co-Founder, Leader Of Reimbursement Strategy
    Humacyte 2014 - 2018
    Durham, Nc, Us
    I played a key role in corporate growth for my last several years with the organization – focusing on reimbursement, commercial development, and patent strategy. I advanced the bioengineered blood vessel platform from discovery to Phase 3 trials, securing advantageous regulatory designations, building a robust pipeline, and negotiating value-based reimbursement paths with CMS.My work led to significant funding rounds, including a $150M Series B, and positioned the organization for a successful NASDAQ listing (HUMA), a BLA under active FDA review, and a positive readout on a pipeline Phase 3 clinical study showing superiority over first line therapy. I am so proud of our achievements and the impact we made in regenerative medicine.
  • Humacyte
    Co-Founder, Vp Technology And Pipeline Development
    Humacyte 2012 - 2014
    Durham, Nc, Us
    I pioneered technological advancements and pipeline expansion strategies as I advanced innovative initiatives from concept to clinical trials. I led cross-functionally to bring 3 programs into the clinic with successful INDs, and I led 3 additional programs into late preclinical stage development. I represented Humacyte externally in the lay press and and as a speaker at scientific and medical meetings to share our progress.By building strategic alliances and securing non-dilutive funding, I enhanced the clinical and preclinical pipelines, and scaled novel manufacturing systems. By tripling our IP portfolio, I captured the value we created as assets for the company.
  • Humacyte
    Co-Founder, Senior Director Of Scientific Operations | Principal Scientist
    Humacyte 2004 - 2012
    Durham, Nc, Us
    I built our internal R&D teams, and led all scientific operations and research initiatives. I strengthened scientific operations and research initiatives to improve efficiency and productivity in preclinical development and scalable GMP manufacturing processes. With the R&D team under me, we pioneered major breakthroughs in product development and biomanufacturing to deliver on a clinically meaningful product platform in a novel scalable manufacturing system, enabling GMP production for clinical trials and the efficiency of operations that comes with scale. Leading R&D teams, I fostered a culture of innovation that resulted in breakthrough advancements in therapeutic development. I also led key partnerships for preclinical studies and for expanding manufacturing capabilities to reinforce the company’s scientific leadership and competitive edge. I partnered across functions to align with regulators on designations and data packages for INDs, to empower future achievements and growth.
  • Duke University
    Adjunct Faculty, Department Of Surgery
    Duke University 2013 - 2018
    Durham, North Carolina, Us
    I enjoyed translational medical research in vascular disease, and retrospective analysis of ESRD patient data with the goal of defining the patient journey and treatment costs, in collaboration with clinical colleagues.
  • Harvard Medical School
    Research In Orthopedic Surgery
    Harvard Medical School 1998 - 1999
    Boston, Ma, Us
    My research focused on osteoblast cell phenotype and functional changes with exposure to extracellular matrix, providing insights on the biology of fibrosis.

Shannon Dahl Skills

Biotechnology Life Sciences R&d Cell Culture Tissue Engineering Fda Regenerative Medicine Strategic Partnerships Reimbursement Technology Transfer Organizational Leadership Medical Devices Clinical Trials Research And Development New Product Strategy Medical Innovation Policy U.s. Food And Drug Administration Clinical Research Stakeholder Engagement Leadership Corporate Development

Shannon Dahl Education Details

  • Massachusetts Institute Of Technology
    Massachusetts Institute Of Technology
    Concentration In Economics
  • Duke University
    Duke University
    Biomedical Engineering (Regenerative Medicine)
  • The George Washington University
    The George Washington University
    Boardroom Ready Corporate Governance For Executive Women In Bio (Adapted From Biogen'S Program)

Frequently Asked Questions about Shannon Dahl

What company does Shannon Dahl work for?

Shannon Dahl works for Carve Bio

What is Shannon Dahl's role at the current company?

Shannon Dahl's current role is Visionary Biotechnology Executive, Chief Scientific Officer, Board Advisor || Driving Innovation from Discovery to Go-to-Market || Offering Expertise in R&D, Commercialization, and Strategic Growth.

What is Shannon Dahl's email address?

Shannon Dahl's email address is sh****@****ail.com

What is Shannon Dahl's direct phone number?

Shannon Dahl's direct phone number is +161239*****

What schools did Shannon Dahl attend?

Shannon Dahl attended Massachusetts Institute Of Technology, Duke University, The George Washington University.

What skills is Shannon Dahl known for?

Shannon Dahl has skills like Biotechnology, Life Sciences, R&d, Cell Culture, Tissue Engineering, Fda, Regenerative Medicine, Strategic Partnerships, Reimbursement, Technology Transfer, Organizational Leadership, Medical Devices.

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant

Download 750 million emails and 100 million phone numbers

Access emails and phone numbers of over 750 million business users. Instantly download verified profiles using 20+ filters, including location, job title, company, function, and industry.